- Home
- FBYD vs LXRX Comparison
FBYD vs LXRX Comparison
Compare FBYD & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBYD
- LXRX
- Stock Information
- Founded
- FBYD 2021
- LXRX 1995
- Country
- FBYD United States
- LXRX United States
- Employees
- FBYD N/A
- LXRX N/A
- Industry
- FBYD
- LXRX Biotechnology: Pharmaceutical Preparations
- Sector
- FBYD
- LXRX Health Care
- Exchange
- FBYD Nasdaq
- LXRX Nasdaq
- Market Cap
- FBYD 468.0M
- LXRX 552.4M
- IPO Year
- FBYD N/A
- LXRX 2000
- Fundamental
- Price
- FBYD $10.50
- LXRX $1.46
- Analyst Decision
- FBYD
- LXRX Buy
- Analyst Count
- FBYD 0
- LXRX 5
- Target Price
- FBYD N/A
- LXRX $3.23
- AVG Volume (30 Days)
- FBYD 44.2K
- LXRX 2.6M
- Earning Date
- FBYD 11-13-2025
- LXRX 11-11-2025
- Dividend Yield
- FBYD N/A
- LXRX N/A
- EPS Growth
- FBYD N/A
- LXRX N/A
- EPS
- FBYD 0.43
- LXRX N/A
- Revenue
- FBYD $7,688,000.00
- LXRX $58,432,000.00
- Revenue This Year
- FBYD N/A
- LXRX $66.55
- Revenue Next Year
- FBYD N/A
- LXRX N/A
- P/E Ratio
- FBYD $24.60
- LXRX N/A
- Revenue Growth
- FBYD 9.17
- LXRX 1504.83
- 52 Week Low
- FBYD $3.62
- LXRX $0.28
- 52 Week High
- FBYD $16.35
- LXRX $2.08
- Technical
- Relative Strength Index (RSI)
- FBYD 46.48
- LXRX 54.82
- Support Level
- FBYD $10.26
- LXRX $1.36
- Resistance Level
- FBYD $12.45
- LXRX $1.58
- Average True Range (ATR)
- FBYD 1.17
- LXRX 0.10
- MACD
- FBYD -0.26
- LXRX -0.02
- Stochastic Oscillator
- FBYD 31.37
- LXRX 34.67
About FBYD Falcon's Beyond Global Inc.
Falcons Beyond Global Inc. is a Company that provides a full range of theme park design, master planning, and experiential technologies for customers in the entertainment and attraction industry through its Falcon's Creative Group reportable segment and develops and co-owns resort and theme park attractions through its Destinations Operations. The Company has four operating segments, Falcon's Creative Group, PDP, Falcon's Beyond Brands, and Destinations Operations, all of which are reportable segments. It earns the majority of the revenue from Falcon's Creative Group segment.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.